CVS Health Corporation, based in Rhode Island, offers healthcare services through various platforms, including retail pharmacies, pharmacy benefits management, and insurance. With a market cap of $101.4 billion, CVS is considered a large-cap company known for its integrated care and telehealth services.

Despite trading slightly below its October high, CVS stock has gained 11.6% over the past three months, outperforming the S&P 500 Healthcare Sector SPDR. Over the past year, CVS has shown significant growth, climbing 35.3% and 77.9% year-to-date, surpassing industry benchmarks.

CVS’s technical outlook remains positive, trading above its moving averages since August, indicating strong trends. However, a recent setback following Q3 earnings release, driven by non-cash charges, caused a temporary decline in the stock price.

Q3 revenue exceeded expectations at $102.9 billion, with adjusted EPS rising 46.8%. CVS raised its full-year adjusted EPS guidance and cash flow targets, demonstrating confidence in its financial performance and growth prospects.

Compared to its competitors, CVS has shown superior performance, with analysts giving it a “Strong Buy” rating and a mean price target of $91.56, implying further potential upside. This information is for informational purposes only and was originally published on Barchart.com.

Read more at Yahoo Finance: Is CVS Outperforming the Healthcare Sector?